Get started
Viridian Therapeutics, Inc.Viridian Therapeutics, Inc.Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VRDN chart


Full chart

VRDN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.53 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.31 USD
Net income (FY)
‪−237.73 M‬ USD
Revenue (FY)
‪314.00 K‬ USD
Shares float
‪70.47 M‬
Beta (1Y)
2.48

Employees


Employees (FY)
96
Change (1Y)
+10 +11.63%
Revenue / Employee (1Y)
‪3.27 K‬ USD
Net income / Employee (1Y)
‪−2.48 M‬ USD

About Viridian Therapeutics, Inc.


Sector
Health Technology
CEO
Stephen Frank Mahoney
Headquarters
Waltham
Website
viridiantherapeutics.com
Founded
2006
FIGI
BBG002H242Z5
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VRDN news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VRDN is 19.31 USD — it has decreased by −1.83% in the past 24 hours. Watch Viridian Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Viridian Therapeutics, Inc. stocks are traded under the ticker VRDN.
VRDN stock has fallen by −12.27% compared to the previous week, the month change is a −0.67% fall, over the last year Viridian Therapeutics, Inc. has showed a −11.83% decrease.
We've gathered analysts' opinions on Viridian Therapeutics, Inc. future price: according to them, VRDN price has a max estimate of 61.00 USD and a min estimate of 22.00 USD. Watch VRDN chart and read a more detailed Viridian Therapeutics, Inc. stock forecast: see what analysts think of Viridian Therapeutics, Inc. and suggest that you do with its stocks.
VRDN reached its all-time high on Jun 18, 2014 with the price of 2,247.75 USD, and its all-time low was 4.66 USD and was reached on Mar 19, 2020. View more price dynamics on VRDN chart.
See other stocks reaching their highest and lowest prices.
VRDN stock is 4.79% volatile and has beta coefficient of 2.48. Track Viridian Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Viridian Therapeutics, Inc. there?
Today Viridian Therapeutics, Inc. has the market capitalization of ‪1.53 B‬, it has decreased by −5.52% over the last week.
Yes, you can track Viridian Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Viridian Therapeutics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
VRDN earnings for the last quarter are −1.15 USD per share, whereas the estimation was −1.06 USD resulting in a −8.77% surprise. The estimated earnings for the next quarter are −1.04 USD per share. See more details about Viridian Therapeutics, Inc. earnings.
Viridian Therapeutics, Inc. revenue for the last quarter amounts to ‪86.00 K‬ USD, despite the estimated figure of ‪84.92 K‬ USD. In the next quarter, revenue is expected to reach ‪44.00 K‬ USD.
VRDN net income for the last quarter is ‪−76.69 M‬ USD, while the quarter before that showed ‪−64.99 M‬ USD of net income which accounts for −18.00% change. Track more Viridian Therapeutics, Inc. financial stats to get the full picture.
No, VRDN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 96.00 employees. See our rating of the largest employees — is Viridian Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Viridian Therapeutics, Inc. EBITDA is ‪−281.48 M‬ USD, and current EBITDA margin is ‪−80.61 K‬%. See more stats in Viridian Therapeutics, Inc. financial statements.
Like other stocks, VRDN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viridian Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Viridian Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Viridian Therapeutics, Inc. stock shows the neutral signal. See more of Viridian Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.